Breaking News


Anti-TNF-alpha therapy increases the risk of psoriasis in patients with rheumatoid arthritis


Antitumor necrosis factor (TNF) alpha therapy is commonly used to treat severe rheumatoid arthritis (RA) and has been proven efficacious in psoriatic arthritis, a condition which involves the combined occurrence of psoriasis and inflammatory arthritis. However, the findings of a recent observational cohort study in patients from the British Society for Rheumatology Biologics Register (BSRBR) suggest that anti-TNF-alpha therapy in patients with RA may be associated with an elevated risk of developing psoriasis compared to treatment with traditional disease-modifying antirheumatic drugs (DMARDs). Patients who had received anti-TNF-alpha therapy (n = 9,826) and a comparison cohort treated with DMARDs (n = 2,880 patients) participated in the study. Anti-TNF-alpha therapy included administration of the ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list